Methods For Preventing Or Treating Allergy By Administering An Il-4R Antagonist

Dupilumab is a therapeutic antibody for treating allergies, specifically targeting IL-4Rα. The drug achieves this by selectively binding to the IL-4Rα receptor, preventing the activation of IL-4 and IL-13, key cytokines involved in allergic responses. Dupilumab is administered subcutaneously and has been shown to effectively reduce serum allergen-specific IgE levels in patients with moderate-to-severe allergies, including asthma and food allergies, by up to 50% compared to baseline. It is particularly effective in patients with sensitization to multiple allergens.